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Abstract
Approximately 10% of cancers use recombination-mediated Alternative Lengthening of Telomeres (ALT) instead of
telomerase to prevent telomere shortening. A characteristic of cells that utilize ALT is the presence of ALT-associated PML
nuclear bodies (APBs) containing (TTAGGG)n DNA, telomere binding proteins, DNA recombination proteins, and
heterochromatin protein 1 (HP1). The function of APBs is unknown and it is possible that they are functionally
heterogeneous. Most ALT cells lack functional p53, and restoration of the p53/p21 pathway in these cells results in growth
arrest/senescence and a substantial increase in the number of large APBs that is dependent on two HP1 isoforms, HP1a and
HP1c. Here we investigated the mechanism of HP1-mediated APB formation, and found that histone chaperones, HIRA and
ASF1a, are present in APBs following activation of the p53/p21 pathway in ALT cells. HIRA and ASF1a were also found to
colocalize inside PML bodies in normal fibroblasts approaching senescence, providing evidence for the existence of a
senescence-associated ASF1a/HIRA complex inside PML bodies, consistent with a role for these proteins in induction of
senescence in both normal and ALT cells. Moreover, knockdown of HIRA but not ASF1a significantly reduced p53-mediated
induction of large APBs, with a concomitant reduction of large HP1 foci. We conclude that HIRA, in addition to its physical
and functional association with ASF1a, plays a unique, ASF1a-independent role, which is required for the localization of HP1
to PML bodies and thus for APB formation.
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Introduction
Alternative Lengthening of Telomeres (ALT) is a telomere
length maintenance mechanism that does not involve telomerase
[1,2], and is utilized by many types of tumors including sarcomas
and astrocytomas [3]. Although the molecular details of the ALT
mechanism in human cells are incompletely understood [4],
previous studies have indicated that ALT involves recombination-
mediated DNA replication [5,6]. With a few exceptions [7–10],
human ALT-positive cells have the hallmarks of (1) a characteristic
pattern of telomere length heterogeneity, with telomeres that
range from very short to greater than 50 kb long [1], and (2) the
presence of ALT-associated promyelocytic (PML) nuclear bodies
(APBs) containing (TTAGGG)n DNA and telomere-specific
binding proteins [11].
APBs are a subset of PML bodies that are present only in ALT
cells, and are not found in mortal cells or telomerase-positive cells
[11]. In addition to the constitutive components of PML bodies
such as PML and Sp100, telomeric DNA and telomere-associated
proteins such as TRF1, TRF2, TIN2 and RAP1 [11–13], they also
contain other proteins involved in DNA replication, recombina-
tion and repair including RAD51, RAD52, and RPA [11],
RAD51D [14], BLM [15,16], WRN [17], BRCA1 [12], MRE11,
RAD50, and NBS1 [18,19], ERCC1 and XPF [20], hRAD1,
hRAD9, hRAD17, and hHUS1 [21], FANCD2 [22], Rif1 [23]
and hnRNP A2 [24]. Formation of APBs requires NBS1, which
recruits MRE11, RAD50 and BRCA1 into these structures
[12,25]. We previously induced APB accumulation with methio-
nine restriction, and used RNAi-based protein depletion to extend
the list of proteins shown to be required for APB formation to
include PML, TRF1, TRF2, TIN2, RAP1, MRE11 and RAD50
[13]. It was also reported that the structural maintenance of
chromosomes SMC5/6 complex localizes to APBs in ALT cells
and sumoylates TRF1 and TRF2, and that this plays an essential
role in APB formation [26].
Although definitive evidence is still lacking, it has long been
thought that APBs might have an integral role in the ALT
mechanism [11,12,19,27,28] and, consistent with this suggestion,
inhibition of ALT in some somatic cell hybrids formed by fusion of
ALT and telomerase-positive cell lines resulted in a substantial
decrease in APBs [29]. Moreover, when ALT was inhibited by
sequestration or depletion of the MRE11/RAD50/NBS1 homol-
ogous recombination complex, this was accompanied by suppres-
sion of APBs, providing further evidence for a direct link between
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,5% of exponentially dividing (‘‘normal’’) ALT cells [11], and
most of the APB-positive cells in these ‘‘normal’’ ALT populations
did not incorporate BrdU within 24 hours (which exceeded their
average doubling time), and also displayed an enlarged, flat
morphology, indicating that they are most likely growth-arrested
or senescent. This association with growth arrest/senescence
appears paradoxical if APBs are actually involved in the ALT
mechanism, and we have recently discussed the possibility that
APBs are functionally heterogeneous, with only a subset being
directly involved in ALT-mediated telomere lengthening [4].
Another possibility is that APBs are simply a byproduct of the
ALT process, and this notion was supported by our recent finding
that heterochromatin protein 1 (HP1), which is involved in
chromatin compaction, is present in APBs, and that knockdown of
HP1a and/or HP1c significantly inhibited p53/p21-mediated
APB induction[31]. This indicated that HP1 is required for APB
formation, and that it is likely that APBs contain ‘‘closed’’
telomeric chromatin and are not the sites of telomere-telomere
recombination. In an attempt to understand the nature of HP1-
mediated chromatin compaction in APB formation, we have now
investigated possible roles for two chromatin regulators/histone
chaperones HIRA and ASF1a in the process of APB formation.
HIRA has features of both the yeast Hir1p and Hir2p proteins
[32], while ASF1a and ASF1b are two orthologs of yeast Asf1p
protein [33,34]. Yeast Hir and Asf1p proteins contribute to
formation of transcriptionally silent heterochromatin, which is
largely responsible for silencing telomeres and mating loci [35–40].
Telomeric silencing in yeast requires physical interaction between
Hir and Asf1p proteins [41]. Similarly, human HIRA and ASF1a
display histone chaperone activity [42–44], and their physical
association is essential for formation of senescence-associated
heterochromatin foci (SAHF) [45,46], which is one of the
molecular characteristics of normal senescent cells [45,47]. SAHF
contain several molecular markers of transcriptionally silent
heterochromatin such as HP1. It has been previously shown that,
prior to their incorporation into SAHF, HP1 proteins are
transiently localized to PML bodies, where they colocalize with
HIRA [45]. More importantly, recruitment of HIRA into PML
bodies is one of the earliest steps towards senescence in human
cells [45]. Although its function inside PML bodies is largely
unknown, blocking entry of HIRA to PML bodies prevents
formation of SAHF [48].
We found that HIRA is present inside APBs in ALT cells in
which the p53/p21 pathway has been restored and showed, for the
first time, that ASF1a colocalizes with HIRA inside APBs in ALT
cells as well as in PML bodies in normal cells. Knockdown of
HIRA, but not ASF1a, significantly decreased the p53/p21-
mediated induction of APBs, suggesting that HIRA is required for
HP1-mediated APB formation in this context. Furthermore, we
found that ASF1a accumulated inside nucleoli of proliferating but
not senescent cells, demonstrating a link between senescence and
release of ASF1a from nucleolar sequestration.
Results
HIRA and ASF1a are localized in APBs upon p53/p21-
mediated senescence
As noted above, large APBs (henceforth referred to as APBs) are
usually found in ,5% of cells within asynchronously growing ALT
cell populations [11]. They can be detected interchangeably by
either telomeric FISH or immunostaining of TRF1 or TRF2
[13,25,31]. Because not every PML body in ALT cells contains
telomeric components, the term ‘‘PML body’’ is not equivalent to
the term ‘‘APB’’; ‘‘APB’’ is used if telomere components are
detected, otherwise ‘‘PML body’’ is used. In this study, APBs were
generally detected by visualizing TRF1 or TRF2 within a PML
body, but were also identified as large, bright TRF1, TRF2 or
telomeric DNA foci (Figure S1), because the quantity of telomeric
DNA and telomeric binding proteins that APBs contain is greater
than the amount present at individual telomeres. As shown in
Figure S1, sometimes individual telomeres can form small foci
with PML, which are much fainter than APBs. Similar structures
have recently been reported in human astrocytoma tissues [49].
The proportion of APB-positive cells can be greatly increased by
restoration of the p53 pathway in p53-negative ALT cells, and this
increase in APB formation is mediated by HP1 proteins [31]. On
the basis of this information and the observation that HP1 proteins
colocalize with HIRA in PML bodies upon onset of senescence in
normal human fibroblasts [45], we wanted to determine whether
HIRA and its binding partner ASF1a are involved in APB
formation. First, we examined localization of HIRA and ASF1a in
relation to APBs in two p53-estrogen receptor (ER) fusion gene-
transfected IIICF/c cell lines, c/p53ER/7 and c/p53ER/8
(abbreviated to C7 and C8), in which p53 function can be
activated by exposure to 4-hydroxytamoxifen (4OHT) [50].
IIICF/c is an ALT cell line [51] derived from IIICF Li-Fraumeni
Syndrome fibroblasts containing one mutant (essentially null) and
one wild-type (wt) TP53 allele [52], that became immortalized
spontaneously via a series of genetic changes that included loss of
the wt TP53 allele [51].
Treatment of C7 and C8 cells with 4OHT upregulated the level
of p21 (Figure 1A), resulting in a senescent phenotype, and a
significant increase in the proportion of cells containing APBs,
some of which showing the presence of p21 inside APBs [31],
within 4 days (Figure S2). Immunostaining analysis on asynchro-
nously growing (untreated) C7 and C8 cells showed that HIRA
and ASF1a were localized in the nucleus, with HIRA being
excluded from and ASF1a being highly concentrated inside
nucleoli (Figure 1B). In a small proportion (,0.7%) of the cell
population, there were nuclear foci outside of the nucleoli
containing both HIRA and ASF1a. When C7 and C8 cells were
treated with 4OHT for 4 days, there was a very large increase in
the proportion of cells (,24%) containing HIRA/ASF1a foci. In
essentially all of these foci ASF1a was found to colocalize with
HIRA inside PML bodies (Figure 1C). Triple immunostaining of
TRF2, PML and HIRA or ASF1a on 4OHT-treated C7 and C8
cells revealed the presence of HIRA and ASF1a inside APBs in
,55% of APB-positive C7 and C8 cells at day 4 of the treatment
(Figure 1D). Some HIRA/ASF1a foci in these cells occurred in
PML bodies other than APBs. HIRA and ASF1a were also found
to colocalize inside PML bodies in .70% of the normal senescent
IMR-90 fibroblast population (Figure 1C). This is the first time
that ASF1a has been found to localize to PML bodies and
colocalize with HIRA in senescent ALT or normal cells.
Distinctive HIRA foci were able to be detected inside PML
bodies as early as one day after 4OHT-treatment, at which point
the ASF1a colocalization was weak or non-existent (Figure 2A), in
contrast to the strong ASF1a foci at day 4 (Figure 1C). These data
suggest that HIRA is recruited to PML bodies earlier than ASF1a,
implying that localization of HIRA to PML bodies is not
dependent on its physical association with ASF1a. To confirm
this, we performed knockdown of HIRA or ASF1a, 48 h prior to
the onset of 4OHT-mediated induction of p53, with two HIRA
siRNAs (HIRA-2 and HIRA-4) or two ASF1a siRNAs (ASF1a and
ASF1a-2), the effectiveness of which was demonstrated by Western
analysis (Figure 2B). We found that HIRA was present inside the
PML bodies in the cells depleted of ASF1a, but not vice versa for
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that HIRA is able to translocate to PML bodies independent of
ASF1a.
HIRA, but not ASF1a, is required for p53/p21-mediated
APB induction
The presence of both HIRA and ASF1a inside APBs led us to
determine whether HIRA and/or ASF1a are involved in p53/
p21-mediated induction of APBs. HIRA or ASF1a siRNAs were
transfected into C7 cells 48 h prior to a 3-day treatment with
4OHT. We found that knockdown of HIRA significantly inhibited
the p53/p21-mediated induction of APBs, whereas knockdown of
ASF1a had no significant impact on APB formation (Figure 3A).
However, when quantitation was carried out for the total cell
populations, only a ,20% reduction in APB formation was
obtained for cells treated with HIRA-siRNAs (Table 1). The
reasons for this apparent discrepancy are that (1) only a portion of
the siRNA-treated cell population was effectively depleted of the
Figure 1. Presence of ASF1a and HIRA inside PML bodies in ALT cells and normal fibroblasts. (A) p21 was upregulated in C7 and C8 cells,
that express a p53-ER fusion protein, after 4 days of 4OHT-treatment. The western blot was probed with the indicated antibodies. (B) Untreated,
proliferating C7 cells were stained for ASF1a and HIRA. No ASF1a and HIRA foci were present in these nuclei. (C) Triple immunofluorescence of ASF1a,
HIRA and PML in C8 cells treated with 4OHT for 4 days, and in senescent IMR-90 fibroblasts, showed colocalization of ASF1a and HIRA in PML bodies.
(D) Immunostaining showed colocalization of ALT-associated PML bodies (APBs; visualized here as large TRF2 foci) and ASF1a or HIRA in C7 and C8
cells treated with 4OHT for 4 days. The antibodies used for this figure and subsequent figures are described in Materials and Methods and are only
specified in the figure legends when Materials and Methods lists more than one antibody against that protein; here the mouse anti-HIRA (B, C), rabbit
anti-HIRA (D), mouse anti-p21 (A), goat anti-p21 (D) and goat anti-PML (C) antibodies were used. Bars, 20 mm.
doi:10.1371/journal.pone.0017036.g001
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varied efficacies of individual siRNAs; and (2) only 50–60% of the
C7 or C8 cell populations are p53/p21-inducible upon addition of
4OHT. These two factors limit the number of cells which are both
p53/p21-induced and also depleted of the target protein.
To overcome this intrinsic property of the p53ER inducible
system, we used another ALT cell line, IIICF-T/B3, that was
established by transfecting IIICF cells with an SV40 early region
expression plasmid [53]; these cells retain a wt TP53 allele. As
shown previously [31], p53 function can be restored in IIICF-T/
B3 cells by knockdown of SV40 large T antigen (LTAg) with an
siRNA against the SV40 early region transcripts (SV40T siRNA),
which results in upregulation of p21, a senescent phenotype, and a
significant increase in APB formation (Figure S3). Simultaneous
knockdown of LTAg and any target proteins in IIICF-T/B3 cells
can achieve, to a large extent, both p53/p21-induction and
depletion of the target proteins. Thus, counting only the cells
depleted of LTAg should result in much more accurate
quantitation. We therefore performed double knockdown of
LTAg and HIRA or ASF1a in IIICF-T/B3 cells with a
combination of SV40T siRNA and HIRA siRNAs (HIRA-2 or
HIRA-4), or ASF1a siRNAs (ASF1a or ASF1a-2). APB-positivity
was scored for the LTAg-depleted cells, revealing that knockdown
of HIRA inhibited the p53/p21-mediated induction of APBs by
Figure 2. Localization of HIRA in PML bodies is independent of ASF1a. (A) C7 cells were triple stained for ASF1a, HIRA and PML 24 h after
treatment with 4OHT. At this early time point, HIRA was more readily detected inside PML bodies than ASF1a. (B) The effectiveness of ASF1a siRNAs
(ASF1a and ASF1a-2) and HIRA siRNAs (HIRA-2 and HIRA-4) was demonstrated in IIICF-T/B3 cells by Western blots, that were probed with the
indicated antibodies. (C) Triple immunostaining of ASF1a, HIRA and PML in C7 cells after treatment with the indicated combinations of siRNAs for 5
days, and with 4OHT for 3 days before the end of siRNA-treatment. Distinct HIRA foci colocalized with PML bodies in cells depleted of ASF1a, while
ASF1a was absent from PML bodies in cells depleted of HIRA. The arrows indicate cells with knockdown of ASF1a (top row) or HIRA (bottom row).
Antibodies used here included mouse anti-HIRA (A, C), rabbit anti-HIRA (B) and goat anti-PML (A, C). Bars, 20 mm.
doi:10.1371/journal.pone.0017036.g002
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(Figure 3B and Table 2). Moreover, simultaneous knockdown of
HIRA and ASF1a had no additive effect in inhibiting APB
formation as compared to knockdown of HIRA alone (Table 3),
which confirms the conclusion that ASF1a has no involvement in
APB formation.
HP1 proteins are present in APBs and are required for APB
formation upon p53/p21-mediated growth arrest/senescence
[31]. As expected, HIRA colocalized with HP1 inside PML
bodies in 4OHT-treated C7 and C8 cells (Figure 4A, and data not
shown). To examine possible involvement of HIRA in the
formation of APB-associated, large HP1a foci, we transfected
IIICF-T/B3 cells with a combination of SV40T siRNA and
siRNAs against HIRA, ASF1a or HP1a. We found that
knockdown of HIRA reduced p53/p21-mediated induction of
large HP1a foci by 37–45%, whereas depletion of ASF1a resulted
in no apparent reduction (Figure 4B and Table 4). Although a
greater reduction was achieved by the control HP1a-knockdown,
the amount of reduction obtained by HIRA-knockdown was
significant, and compatible with the extent to which it reduced
Figure 3. HIRA is required for p53/p21-mediated induction of APBs. (A) Triple immunostaining with the indicated antibodies in C7 cells after
treatment with HIRA or ASF1a siRNA for 5 days, and with 4OHT for 3 days before the end of siRNA-treatment. Knockdown of HIRA, but not ASF1a,
largely prevented p53/p21-mediated induction of APBs. The arrows indicate cells with knockdown of HIRA (top row) or ASF1a (bottom row). (B) IIICF-
T/B3 cells were stained for SV40T, p21 and TRF1 4 days after transfection of the indicated combinations of siRNAs. HIRA siRNA (HIRA-2), but not ASF1a
siRNA (ASF1a-2), significantly suppressed SV40T siRNA-mediated induction of APBs (visualized here as large TRF1 foci). Antibodies used here included
rabbit anti-HIRA (A), goat anti-p21 (B) and goat anti-PML (A). Bars, 20 mm.
doi:10.1371/journal.pone.0017036.g003
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indispensable for p53/p21-mediated induction of APBs.
Although ASF1a, unlike HIRA, is dispensable for p53/p21-
mediated APB formation, the occurrence of APBs in senescent ALT
cells made it important to determine whether either or both of these
proteinsarerequiredforSAHF formationin4OHT-treated C7and
C8 cells. We therefore performed knockdown of ASF1a or HIRA in
C7 and C8 cells, 48 h prior to a 4-day treatment with 4OHT, with
ASF1a or HIRA siRNAs, and found that depletion of ASF1a or
HIRA, resulted in a significant reduction on SAHF formation
(Figure S4 and Table S1), which is consistent with the previous
studies indicating that both proteins are required for SAHF
formation in normal senescent fibroblasts [45,48].
ASF1b is absent from APBs and dispensable for APB
formation
Human cellshavetwoASF1 paralogs,ASF1a and ASF1b.Unlike
ASF1a, ASF1b does not physically intact with HIRA [43,45], but
instead forms complexes with chromatin assembly factor 1 (CAF-1)
[54]. Despite the lack of physical interaction between ASF1b and
HIRA, it was of interest to determine whether there is any
functional redundancy between ASF1a and ASF1b with regard to
p53/p21-mediated APB formation. We first examined the locali-
zation of ASF1b by triple immunostaining of ASF1b, TRF2 and
PML, and found that ASF1b did not form foci inside APBs, but was
distributed homogeneously in the nuclei (Figure 5A). We then
performed triple knockdown of LTAg, ASF1a and ASF1b in IIICF-
T/B3 cells with SV40T siRNA, ASF1a siRNAs, and two siRNAs
against ASF1b(ASF1bandASF1b-2), the effectivenessofwhichwas
demonstrated by Western analysis (Figure 5B). We found that, like
knockdown of ASF1a and ASF1b individually, simultaneous
knockdown of these proteins did not block p53/p21-mediated
APB induction (Figure 5C and Table 3). The data indicate that
neither ASF1a nor ASF1b is required for APB formation and that
they have no functional redundancy in this context.
Strong nucleolar presence of ASF1a in proliferating
cancer and normal cells
During the course of the study, we found that ASF1a
accumulated inside the nucleoli of proliferating C7 and C8 cells
(Figure 6A), and upon 4OHT-treatment, this accumulation
gradually disappeared from the majority of cells in the population
(Figure 6B), suggesting that nucleolar localization of ASF1a is
associated with cell growth and its release from nucleoli is
associated with growth arrest. The specificity of the nucleolar
ASF1a staining was confirmed by two ASF1a siRNAs (Figure S5,
and data not shown), and nucleolar markers B23 (nucleophosmin/
NPM) and ki-67 (Figure 6A and 6B). We extended the analysis of
ASF1a localization to other cell types. Nucleolar ASF1a
accumulation was observed in IIICF/c cells, normal IMR-90
fibroblasts and telomerase-positive HeLa cells (Figure 6C). HIRA
did not accumulate inside the nucleolus (Figure 1B), and double
staining of ASF1b and B23 in C7 and C8 cells revealed that only a
small portion of the population displayed prominent nucleolar
ASF1b localization, which is much less frequent than that of
ASF1a (Figure S6), suggesting that ASF1a and ASF1b may have
different roles in regulating cell growth.
Table 1. Proportion of APB-positive C7 cells after treatment
with siRNAs and 4-hydroxytamoxifen (4OHT).
siRNA-treatment
a Total APB+(%)
none 216 92 (42.6)
control 203 79 (38.9)
ASF1a 207 84 (40.6)
ASF1a-2 206 90 (43.7)
HIRA-2 211 67 (31.8)
HIRA-4 218 61 (28.0)
aCells were transfected with 10 nM siRNA 48 h prior to the addition of 1 mM
4OHT, which was maintained for another 3 days. None, no siRNA-treatment;
control, non-silencing control siRNA.
doi:10.1371/journal.pone.0017036.t001
Table 2. Proportion of APB-positive IIICF-T/B3 cells after
siRNA-treatment.
siRNA-treatment
a Total (SV40T-)
b APB+(%)
SV40T+C 104 57 (54.8)
SV40T+p21-6 110 28 (25.5)
SV40T+ASF1a 112 63 (56.3)
SV40T+ASF1a-2 109 57 (52.3)
SV40T+HIRA-2 107 38 (35.5)
SV40T+HIRA-4 106 34 (32.1)
SV40T+C 108 66 (61.1)
SV40T+p21-6 103 29 (28.2)
SV40T+ASF1a 99 58 (58.6)
SV40T+ASF1a-2 115 62 (53.9)
SV40T+HIRA-2 104 35 (33.7)
SV40T+HIRA-4 110 40 (36.4)
aCells were treated with 10 nM siRNA per target for 4 days before being fixed
for immunostaining. C, non-silencing control siRNA.
bOnly cells that were negative by immunostaining for SV40T were examined for
APBs.
doi:10.1371/journal.pone.0017036.t002
Table 3. Proportion of APB-positive IIICF-T/B3 cells after
siRNA-treatment.
siRNA-treatment
a Total (SV40T-)
b APB+(%)
SV40T+C+C 103 60 (58.3)
SV40T+ASF1a-2+ASF1a-2 108 65 (60.2)
SV40T+ASF1a-2+HIRA-4 102 36 (35.3)
SV40T+HIRA-4+HIRA-4 111 33 (29.7)
SV40T+HP1a-2+HP1c-6 107 28 (26.2)
SV40T+C+C 123 69 (56.1)
SV40T+C+HIRA-4 115 40 (34.8)
SV40T+ASF1a-2+HIRA-4 126 42 (33.3)
SV40T+C+C 110 63 (57.3)
SV40T+C+p21-6 113 34 (30.1)
SV40T+C+ASF1b 107 59 (55.1)
SV40T+C+ASF1b-2 105 62 (59.0)
SV40T+ASF1a+ASF1b 114 66 (57.9)
SV40T+ASF1a-2+ASF1b-2 115 71 (61.7)
aCells were treated with 10 nM siRNA per target for 4 days before being fixed
for immunostaining. C, non-silencing control siRNA.
bOnly cells that were negative by immunostaining for SV40T were examined for
APBs.
doi:10.1371/journal.pone.0017036.t003
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We previously showed that the heterochromatin proteins, HP1a
and c, are required for formation of APBs in ALT cells upon p53/
p21-mediated senescence [31]. Here we have shown that another
heterochromatin regulator, HIRA, is involved in both APB
formation and SAHF formation, a key step in establishing the
senescent phenotype, and a further heterochromatin regulator,
ASF1a, is involved in SAHF formation. These findings tighten the
correlation between induction of APBs and senescence, consistent
with the observation that knockdown of p21, a major downstream
regulator of p53-mediated senescence, significantly reduces p53-
mediated induction of APBs [31], and provide new insights into
the mechanisms involved in this process.
We have not found any fundamental differences between APBs
in asynchronously growing ALT cell populations and those where
senescence is experimentally induced. Only a small minority of
asynchronously growing ALT cells have large APBs, and most of
these appear to be growth arrested/senescent (T. Yeager and R.
Reddel, unpublished data); the causes of growth arrest in these
cells may include mitotic accidents. This is consistent with the
results from our recent study [31] showing that APB formation is
associated with growth arrest/senescence. The demonstration of
HIRA’s involvement in HP1-mediated APB formation further
supports the notion that APBs are likely to contain ‘‘closed’’
telomeric chromatin, which is unlikely to permit telomere-
telomere recombination. Given this and the lack of direct evidence
for de-novo telomere lengthening inside APBs, we suggest that
APBs may simply be a byproduct of the ALT process.
Although the function of HIRA inside PML bodies is largely
unknown, its relocalization there is an early step in the senescence
program induced by short telomeres, activated oncogenes or cell
stress [48], and physical interaction of HIRA and ASF1a is
required for SAHF formation in senescing normal cells [45]. It has
been proposed that HIRA-containing complexes are assembled or
Figure 4. HIRA is required for p53/p21-mediated formation of large HP1 foci. (A) Triple immunostaining showed colocalization between
HIRA and HP1a inside PML bodies in C7 cells treated with 4OHT for 2 days. (B) IIICF-T/B3 cells were stained for SV40T, HP1a and PML 4 days after
transfection of the indicated combinations of siRNAs (T, SV40T; C, control). HIRA siRNA (HIRA-4), but not ASF1a siRNA (ASF1a), largely blocked SV40T
siRNA-mediated induction of large HP1a foci. Antibodies used here included rabbit anti-HIRA (A), mouse anti-HP1a (A), rabbit anti-HP1a (B) and goat
anti-PML (A, B). Bars, 20 mm.
doi:10.1371/journal.pone.0017036.g004
Table 4. Proportion of IIICF-T/B3 cells with large HP1a-foci
after siRNA-treatment.
siRNA-treatment
a Total (SV40T-)
b Large HP1a foci+ (%)
SV40T+C+C 116 72 (62.1)
SV40T+C+HP1a-2 127 20 (15.7)
SV40T+C+ASF1a 118 75 (63.6)
SV40T+C+ASF1a-2 114 67 (58.8)
SV40T+C+HIRA-2 129 44 (34.1)
SV40T+C+HIRA-4 123 47 (38.2)
SV40T+C+C 105 71 (67.6)
SV40T+C+HIRA-4 112 48 (42.9)
SV40T+HIRA-4+HIRA-4 110 37 (33.6)
SV40T+HIRA-4+ASF1a-2 105 42 (40.0)
aCells were treated with 10 nM siRNA per target for 4 days before being fixed
for immunostaining. C, non-silencing control siRNA.
bOnly cells that were negative by immunostaining for SV40T were examined for
large HP1a-foci.
doi:10.1371/journal.pone.0017036.t004
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and histone H3 to catalyze formation of SAHF elsewhere in the
nucleus [55]. We demonstrated here for the first time that ASF1a
colocalizes with HIRA in PML bodies of senescing fibroblasts (and
in APBs in ALT cells), suggesting that PML bodies are the location
for the HIRA/ASF1a interaction. Intriguingly, we found that
ASF1a is sequestered in the nucleoli of proliferating cells and is
released when senescence is induced, presumably permitting its
interaction with HIRA in PML bodies. This is consistent with a
growing body of evidence that the nucleolus has a role in
regulating specific aspects of cell cycle progression via protein
modifications and protein sequestration [56].
HIRA has been shown to be present at telomeres where it is
thought to function as a histone chaperone [57]. A recent study [58]
has shown that ubinuclein 1 (UBN1) colocalizes with HIRA inside
PML bodies in senescent cells. UBN1 is not only a component of
HIRA/ASF1a complexes, but is also associated with histone
methyltransferase (HMTase) activity toward lysine 9 of histone
H3 (H3K9). HP1 proteins are usually recruited to chromatin,
including telomeric chromatin, through their affinity for trimethy-
lated H3K9 residues[59,60]. Consistent with these observations, we
found that reducing APB formation by knockdown of HIRA was
accompanied by a similar reduction in formation of large HP1 foci,
suggesting that HIRA is required for the association of HP1 with
telomeric chromatin inside PML bodies to form APBs. Based on
these data, we speculate that HIRA may, through its association
with UBN1 and HMTase, modify the methylation state of histone
H3 bound to telomeric DNA as a prerequisite for HP1-mediated
compaction of this DNA and APB formation.
HIRA formed foci inside PML bodies earlier than ASF1a in
ALT cells following restoration of the p53/p21 pathway, and was
able to do so in ASF1a-depleted cells, and knockdown of ASF1a
had no significant effects on formation of APBs and large HP1
foci. These data are consistent with previous reports that
translocation of HIRA to PML bodies in normal pre-senescent
fibroblasts is independent of ASF1a [48,61]. In addition to the
observation that HIRA and ASF1a are both required for SAHF
formation in senescing ALT cells (this study), other relevant
observations are that interaction between HIRA and ASF1a is
required for formation of SAHF in normal senescent fibroblasts,
formation of SAHF occurs much later than recruitment of HIRA
into PML bodies upon senescence, formation of SAHF is not
catalyzed inside PML bodies, and telomeres are excluded from
SAHF [45,55,62]. It is therefore plausible that HIRA could play
an ASF1a-independent role via its association with UBN1 and
HMTase after its entry to PML bodies, and then interact with
ASF1a to form complexes before leaving PML bodies to catalyze
formation of SAHF elsewhere in the nucleus.
We found no ASF1b foci inside APBs or PML bodies and no
evidence that ASF1b had a functional role in APB formation, in
agreement with the observation that ASF1b is unable to bind
HIRA [43,45]. ASF1b had much less nucleolar localization than
Figure 5. ASF1a and ASF1b are both dispensable for APB formation. (A) Triple immunostaining of ASF1b, TRF2 and PML in C7 cells treated
with 4OHT for 4 days. No ASF1b foci were observed inside APBs. (B) The effectiveness of ASF1b siRNAs (ASF1b and ASF1b-2) was demonstrated in
IIICF-T/B3 cells by immunoblotting. The blots were probed with the indicated antibodies. (C) Triple staining of SV40T, p21 and TRF1 in IIICF-T/B3 cells
treated with the indicated combination of siRNAs (T, SV40T; A2, ASF1a-2; B2, ASF1b-2) for 4 days. APBs (visualized here as large TRF1 foci) were still
detected in cells that were negative for SV40T. Antibodies used here included rabbit mAb anti-ASF1b (A), rabbit anti-ASF1b (B), goat anti-p21 (C) and
goat anti-PML (A). Bars, 20 mm.
doi:10.1371/journal.pone.0017036.g005
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ASF1a is involved in both DNA synthesis-coupled and -
independent nucleosome assembly, and ASF1b is only involved
in the former [43–45,54].
In summary, the results from our study show that HIRA but not
ASF1a is required for p53/p21-mediated induction of APBs,
suggesting that HIRA plays a unique, ASF1a-independent role in
this process, and that PML bodies in ALT cells could serve as sites
that integrate two senescence-related cellular processes: (1)
compaction of telomeric DNA by HIRA and HP1, and (2)
assembly of the HIRA/ASF1a complexes needed for SAHF
formation (Figure 7). The requirement for HIRA in both APB and
SAHF formation supports the close correlation between APBs and
senescence of cells that use the ALT mechanism.
Materials and Methods
Cell culture
The spontaneously immortalized Li-Fraumeni Syndrome fibro-
blast line IIICF/c [51], human cervical carcinoma cell line HeLa
and normal human fibroblast strain IMR-90 (ATCC, Manassas,
VA, USA) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM; GIBCO, Rockville, MD, USA). The p53-estrogen
receptor (ER) fusion gene-transfected IIICF/c cell lines, c/
p53ER/7 (C7) and c/p53ER/8 (C8), were cultured in phenol
red-free DMEM (GIBCO) containing 1 mg/ml puromycin [50].
SV40-immortalized Li-Fraumeni Syndrome fibroblast cell line
IIICF-T/B3 [53] was cultured in RPMI 1640 medium (GIBCO).
All culture media contained 10% fetal bovine serum (FBS) and
Figure 6. Accumulation of ASF1a inside nucleoli. (A) Immunostaining of proliferating C7 cells showed colocalization between ASF1a and the
nucleolar marker B23. (B) Triple staining of ASF1a, Ki67 and DNA in C7 cells treated with 4OHT for 4 days. ASF1a was largely absent from the nucleoli
of Ki67-negative cells. (C) ASF1a-staining of proliferating IIICF/c, Hela and IMR-90 cells showed nucleolar localization of ASF1a in all three cell lines.
Bars, 20 mm.
doi:10.1371/journal.pone.0017036.g006
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humidified atmosphere at 37uC.
For p53-induction experiments, C7 and C8 cells were seeded in
phenol red-free DMEM and grown to 30–40% confluency. The
cell cultures were treated with 1 mM 4OHT or 0.01% ethanol as
vehicle control. After various time periods, cells were either fixed
for immunostaining, or harvested for isolation of protein.
Antibodies
The following antibodies were used in this study: rabbit anti-
ASF1a and mouse anti-B23 (ProteinTech Group, Chicago, IL,
USA); rabbit anti-ASF1b (mAb, C70E2), anti-ASF1b and anti-
HP1a (Cell Signaling Technology, Boston, MA, USA); rabbit anti-
HIRA (Abgent, San Diego, CA, USA); mouse anti-HIRA
(Abnova, Taipei, Taiwan); mouse anti-p21, anti-TRF2 and anti-
Ki67 (BD Biosciences, San Jose, CA, USA); goat anti-p21 (R&D
Systems, Minneapolis, MN, USA); mouse anti-p53 (DO1), goat
anti-PML (N-19) and mouse anti-PML (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA); mouse anti-TRF2 and anti-HP1a
(Upstate Biotechnology, Waltham, MA, USA). Mouse anti-SV40T
(PAb108) was purified from the supernatant of hybridoma TIB-
230 (ATCC), and polyclonal anti-TRF1 rabbit serum was raised
against a TRF1 peptide, residues 13–35.
RNA interference
The following siRNAs were designed and synthesized by
Qiagen (Hilden, Germany): for p21, 59-CAGTTTGTGTGTCT-
TAATTAT-39 (p21-6) and for HP1c,5 9-CTGGTTACTTTGAA-
CAAATAA-39 (HP1c-6). The following siRNAs were synthesized
by Qiagen: for SV40T, 59-AAAATTGTGTACCTTTAGCTT-39
[63]; for HP1a (HP1a-2), 59-GAGGAGCACAATACTTGG-
GAA-39 [64]; for HIRA (HIRA-2 and HIRA-4), 59-GGGGA-
GATGACAAACTGATTA-39 and 59-CAGAAATTCTAGC-
TACTCTGA-39 [65]; for ASF1a (ASF1a and ASF1a-2), 59-
AAGTGAAGAATACGATCAAGT-39 [66] and 59-CTGAGA-
CAGAATTAAGGGAAA-39 [67]; and for ASF1b (ASF1b and
ASF1b-2), 59-AACAACGAGTACCTCAACCCT-39 [66] and 59-
GGCGGACGACCTGGAGTGGAA-39 [67]. The non-silencing
control siRNA was purchased from Qiagen.
To determine the extent of knock-down, cells were transfected
with 10 nM siRNA per target gene using HiPerFect transfection
reagent (Qiagen) according to the manufacturer’s instructions. For
Western analysis, cells were seeded into six-well plates 1–2 days
prior to siRNA transfection. After transfection for 48 h, cells were
harvested for protein isolation.
APB screening in SV40-immortalized cell lines by RNA
interference
Cells were seeded into four-well chamber slides (Nunc,
Naperville, IL, USA) two days before transfection of siRNAs.
For double or triple knockdown experiments, 10 nM siRNA per
target gene, and 10 nM SV40T siRNA, were transfected into cells
using HiPerFect. Four days later, cells were fixed and immuno-
stained for SV40T, p21 and TRF1 (large foci of which are
recognized as APBs). Finally, APB-positivity was scored for the
cells in which SV40T was depleted.
Immunostaining, telomere FISH and fluorescence
microscopy
Cells grown in four-well chamber slides were fixed for 15 min in
2% paraformaldehyde at room temperature, and then permeated
with 0.5% Triton X-100 (Sigma-Aldrich, St Louis, MO, USA) at
room temperature for 10 min or methanol:acetone (1:1) at 220uC
for 15 min. Cells were incubated overnight with primary
antibodies at 4uC, and then were incubated with fluorescently
conjugated secondary antibodies at room temperature for 40 min.
In some cases, DAPI (Sigma-Aldrich) was included in the
secondary incubation to visualize DNA. For detection of SAHF,
the samples were stained with 0.13 mg/ml DAPI at room
temperature for 2 min. Finally, the preparations were mounted
in anti-fading medium containing DABCO (Sigma-Aldrich) or
medium consisting of glycerol:PBS (70%:30%). The secondary
antibodies used were as follows: FITC- or Texas Red-conjugated
goat anti-mouse, FITC- or Texas Red-conjugated goat anti-rabbit,
AMCA-, FITC- or Texas Red-conjugated donkey anti-mouse,
AMCA-, FITC- or Texas Red-conjugated donkey anti-rabbit,
AMCA- or Texas Red-conjugated donkey anti-goat (Jackson
ImmunoResearch, West Grove, PA, USA).
Double staining of telomeric DNA and APB-associated proteins
was performed as previously described [68]. Briefly, slides were
first immunostained with primary and secondary antibodies, and
then cross-linked with 4% formaldehyde and dehydrated.
Telomere fluorescence in situ hybridization (FISH) was done by
using a Cy3-conjugated telomere-specific peptide nucleic acid
(PNA) probe (Applied Biosystems, Framingham, MA, USA).
The samples were examined on a Leica DMLB fluorescence
microscope (Leica, Wetzlar, Germany). A PL-FLUOTAR 40x/
NA 0.7 objective was used in this study. Images were recorded
using a Spot cooled CCD camera (SPOT2; Diagnostic Instru-
ments, Sterling Heights, MI, USA) and analyzed with PhotoShop
7.0 (Adobe, San Jose, CA, USA).
SA-b-gal activity assay
Cells were grown in four-well chamber slides to 30–40%
confluency and then treated with 1 mM 4OHT or 10 nM SV40T
siRNA for 3 or 4 days. The SA-b-gal staining was performed with
a SA-b-gal staining kit (Cell Signaling Technology) according to
the manufacturer’s instructions. The samples were examined on
an Olympus IMT-2 inverted microscope (Olympus, Tokyo, Japan)
Figure 7. A hypothetical model for HIRA and ASF1a in APB
formation and senescence in ALT cells. Growth arrest/senescence
signals trigger relocalization of HIRA to PML bodies, which leads to the
subsequent translocation of HP1a/c, telomeric DNA and its associated
shelterin proteins, each of which is essential for APB formation. The
dashed line indicates that translocation of ASF1a to PML bodies and its
colocalization there with HIRA is not essential for APB formation, even
though HIRA and ASF1a are both required for the establishment of the
senescent phenotype in ALT cells.
doi:10.1371/journal.pone.0017036.g007
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using a digital camera (DP12; Olympus) and analyzed with
PhotoShop 7.0 (Adobe).
Immunoblotting
For immunoblotting analyses, cell lysates were prepared,
electrophoretically separated on SDS-PAGE gels and electro-
transferred to a nylon membrane as described previously [69].
Immunoblotting procedures were as recommended by the
antibody suppliers. Horseradish peroxidase (HRP) conjugated
goat anti-mouse, goat anti-rabbit or swine anti-rabbit IgG
(DAKO, Glostrup, Denmark) were used as secondary antibodies.
Supporting Information
Figure S1 APBs can be detected interchangeably by either
telomeric FISH or immunostaining of TRF1 or TRF2. After 4 days
of 4OHT-treatment, APBs were induced in C7 and C8 cells, where
colocalization was observed between prominent TRF1 or TRF2 foci
and large PML bodies (top row), and between telomeric DNA and
TRF1 foci (bottom row). The antibodies used for this supplementary
figure and the subsequent figures are described in Materials and
Methods and are only specified in the figure legends when Materials
and Methods lists more than one antibody against that protein; here
the goat anti-PML antibody was used. Bar, 20 mm.
(TIF)
Figure S2 Induction of APBs is associated with p53/p21-
mediated senescence. (A) SA-b-gal staining of C8 cells treated
with 4OHT or ethanol vehicle for 4 days. SA-b-gal expression was
found in 4OHT-treated C8 cells. (B) Double immunostaining of
TRF1 and p21 in C8 cells treated with 4OHT or ethanol vehicle
for 4 days. Large TRF1 foci were induced in cells positive for p21.
Antibodies used here included mouse anti-p21 (B). Bars, 100 mm
(A) and 20 mm (B).
(TIF)
Figure S3 Induction of APBs in SV40-immortalized ALT cells by
siRNA-mediated knockdown of LTAg. (A) Western blots showed
induction of p21 in IIICF-T/B3 cells 2 days after transfection of
SV40T and control (T+C) siRNAs. This induction of p21 was
effectively abrogated by p21 siRNA (p21-6). The blots were probed
with the indicated antibodies. (B) SA-b-gal staining of IIICF-T/B3
cells treated with the indicated combinations of siRNAs for 3 days.
Strong SA-b-gal expression was found in cells treated with T+C
siRNAs. (C) IIICF-T/B3 cells were triple stained for SV40T, p21
andTRF1 4daysafterSV40TsiRNAtransfection.APBs(visualized
here as large TRF1 foci) were observed in cells with high levels of
p21. Antibodies used here included mouse anti-p21 (A) and goat
anti-p21 (C). Bars, 100 mm (B) and 20 mm (C).
(TIF)
Figure S4 ASF1a and HIRA are both required for SAHF
formation. Triple staining for p21, DAPI and ASF1a or HIRA in
C7 and C8 cells that were transfected with the indicated
combinations of siRNAs (A, ASF1a; A2, ASF1a-2; H2, HIRA-2;
H4, HIRA-4; C, control) 48 h prior to addition of 4OHT, which
was then maintained for another 4 days. Both ASF1a and HIRA
siRNAs significantly inhibited p53/p21-mediated SAHF forma-
tion in C7 and C8 cells. The arrows indicate cells with knockdown
of ASF1a (top panel) or HIRA (bottom panel). The arrowheads
indicate cells with SAHF. Antibodies used here included mouse
anti-HIRA and goat anti-p21. Bars, 20 mm.
(TIF)
Figure S5 Verification of nucleolar ASF1a staining by ASF1a
knockdown. IIICF/c cells were stained for ASF1a 3 days after
transfection of ASF1a or control siRNA. Nucleolar ASF1a staining
was substantially depleted in cells treated with ASF1a siRNA. Bar,
20 mm.
(TIF)
Figure S6 Nucleolar localization of ASF1b is less prominent
than ASF1a. Proliferating C7 cells were double stained for B23
and ASF1a or ASF1b. Nucleolar ASF1b staining was less
prominent than that of ASF1a. Antibodies used here included
rabbit anti-ASF1b mAb. Bar, 20 mm.
(TIF)
Table S1 Proportion of SAHF-positive C7 and C8 cells after
treatment with siRNAs and 4-hydroxytamoxifen (4OHT).
(DOC)
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